Literature DB >> 9965

Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.

R H Mindham.   

Abstract

I have tried to bring out some of the important methodological problems found in examining the effectiveness of drugs used in the control of druginduced parkinsonism by referring mainly to studies in which I have taken part. I hope I have shown that the whole topic is far less well understood than is often assumed. The main points may be summarized as follows: there is doubt as to whether many of the drugs used in controlling drug-induced parkinsonism are really effective; the results of many studies are conflicting; many studies contain serious flaws in design; methods for assessing extrapyramidal signs are not well developed; we are ignorant of the way in which drug-induced extrapyramidal signs change spontaneously. There is a clear need for further research in this area to improve techniques of assessment, to provide basic information on drug-induced syndromes, and to rigorously examine the efficacy of the drugs used in controlling them.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9965      PMCID: PMC1428830          DOI: 10.1111/j.1365-2125.1976.tb03732.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  A SELF-RATING DEPRESSION SCALE.

Authors:  W W ZUNG
Journal:  Arch Gen Psychiatry       Date:  1965-01

2.  A survey of drug-induced extrapyramidal reactions.

Authors:  F J AYD
Journal:  JAMA       Date:  1961-03-25       Impact factor: 56.272

3.  KEMADRIN IN THE TREATMENT OF PARKINSONISM: A DOUBLE BLIND AND ONE-YEAR FOLLOW-UP STUDY.

Authors:  R R STRANG
Journal:  Curr Med Drugs       Date:  1965-04

4.  Reversibility of drug-induced parkinsonism.

Authors:  R B CAHAN; D D PARRISH
Journal:  Am J Psychiatry       Date:  1960-05       Impact factor: 18.112

5.  Withdrawal of maintenance antiparkinson drug in the phenothiazine-induced extrapyramidal reaction.

Authors:  W MANDEL; W A OLIVER
Journal:  Am J Psychiatry       Date:  1961-10       Impact factor: 18.112

6.  Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.

Authors:  R H Mindham; R Gaind; B H Anstee; L Rimmer
Journal:  Psychol Med       Date:  1972-11       Impact factor: 7.723

7.  Evidence for a new type of dopamine receptor stimulating agent.

Authors:  H Corrodi; K Fuxe; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1971-12       Impact factor: 3.765

8.  Effects of L-dopa in Parkinson's disease.

Authors:  R B Godwin-Austen; E B Tomlinson; C C Frears; H W Kok
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

9.  Measurement of behavioural changes in patients on L-dopa.

Authors:  M J Meier; W E Martin
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

10.  A CRITICAL ANALYSIS OF THE EFFECTS OF TRIHEXYPHENIDYL (ARTANE) ON THE COMPONENTS OF THE PARKINSONIAN SYNDROME.

Authors:  J BRUMLIK; G CANTER; R DELATORRE; M MIER; M PETROVICK; B BOSHES
Journal:  J Nerv Ment Dis       Date:  1964-05       Impact factor: 2.254

View more
  4 in total

1.  Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.

Authors:  S G Bowes; P K Clark; A Charlett; C J O'Neill; A L Leeman; C Weller; P W Nicholson; A A Deshmukh; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

3.  Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.

Authors:  R J Hardie; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 4.  Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.

Authors:  Sharadha Wisidagama; Abiram Selladurai; Peter Wu; Marco Isetta; Jordi Serra-Mestres
Journal:  Medicines (Basel)       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.